The Efficacy and Safety of Triple Therapy in Obstructive Lung Disease (ETHOS) and Informing the Pathway of Chronic ...

AGMB-447 is an investigational drug and not approved by any regulatory authority. Its efficacy and safety have not been established.

HORRY COUNTY, S.C. (WBTW) — Four people were displaced after a Monday night house fire in the Forestbrook area, Horry County ...

Warm winds from the south and southwest have brought wildfire smoke into the Ozarks, creating air quality concerns for ...

India, March 29 -- Progressive pulmonary fibrosis (PPF), a serious form of interstitial lung disease, remains one of the most difficult lung conditions to treat.

Top-line results from the OBERON and TITANIA trials showed that tozorakimab reduced the annualised rate of moderate-to-severe ...

GD analyst, Vinie Varkey notes that tozorakimab could capture a "significant patient share" as an add-on therapy in COPD.

With receipt of inhaled treprostinil for 52 weeks, adults with idiopathic pulmonary fibrosis had less FVC decline compared ...

Breathing in common disinfectant chemicals known as quaternary ammonium compounds, or QACs, may be far more harmful than swallowing them, according to a mouse study led by researchers at UC Davis. The ...

AstraZeneca’s tozorakimab meets primary endpoint in both OBERON and TITANIA phase III trials in patients with COPD: Cambridge, UK Saturday, March 28, 2026, 11:00 Hrs [IST] Posit ...

Avalyn Pharma Inc., (“Avalyn” or the “Company”), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases, ...

Antwerp, Belgium, March 26, 2026 - Agomab Therapeutics NV (Nasdaq: AGMB) ("'Agomab'"), a clinical-stage biopharmaceutical company focused on fibrosis, today announced that the United States Patent and ...